Chemotherapy-Induced Oral Mucositis
The mouth sores are chemotherapy-induced oral mucositis, a direct toxic effect of the cytotoxic drugs—particularly methotrexate and fluorouracil—on the rapidly dividing oral mucosal cells. All three agents in this regimen (cyclophosphamide, methotrexate, and fluorouracil) are well-documented causes of oral mucositis 1, 2, 3, 4.
Why This Is Happening
The combination of cyclophosphamide, methotrexate, and fluorouracil (CMF regimen) carries significant mucositis risk. Methotrexate and fluorouracil are particularly notorious for causing oral mucosal damage 4. The FDA label for fluorouracil explicitly warns that "mucositis, stomatitis or esophagopharyngitis, which may lead to mucosal sloughing or ulceration, can occur" 2. Similarly, cyclophosphamide's FDA label documents "oral mucosal ulceration" as a known adverse effect 3.
The pathophysiology involves direct cytotoxic damage to the basal epithelial cells of the oral mucosa, which have high turnover rates similar to cancer cells. This typically manifests 5-7 days after chemotherapy administration and can persist for 1-2 weeks 5.
Management Approach
Immediate Actions
Implement a rigorous oral care protocol immediately 1:
- Brush teeth gently with a soft toothbrush after each meal and before bed
- Rinse mouth with alcohol-free mouthwash at least 4 times daily for 1 minute; avoid eating/drinking for 30 minutes after rinsing 1
- Avoid painful stimuli: smoking, alcohol, citrus fruits, tomatoes, hot drinks, spicy/hot/raw/crusty foods 1
Pain Management
For pain control, use patient-controlled analgesia with morphine or consider 0.2% morphine mouthwash 1. Transdermal fentanyl is an alternative option 1. Topical anesthetics can provide short-term relief 6.
Preventive Measures for Future Cycles
For fluorouracil specifically, implement 30 minutes of oral cryotherapy (ice chips) during bolus administration to prevent mucositis in subsequent cycles 1, 6. This is a Level II recommendation from ESMO guidelines.
Dose Modification
Withhold fluorouracil for Grade 3 or 4 mucositis until it resolves or decreases to Grade 1 severity, then resume at a reduced dose 2. This is critical to prevent progression to severe mucosal sloughing or ulceration.
Critical Monitoring Points
- Assess for infection risk: Patients with mucositis and concurrent myelosuppression face increased risk of sepsis from mucosal barrier breakdown 1
- Monitor nutritional status: Severe oral pain may necessitate enteral nutrition support 1
- Check for concurrent pancytopenia: The combination of mucositis with bone marrow suppression significantly increases mortality risk 3
Common Pitfall
Do not dismiss this as a minor side effect. Grade 3-4 mucositis in the setting of myelosuppression can lead to life-threatening sepsis 1. The CMF regimen causes mucositis in a substantial proportion of patients, with older patients (≥65 years) experiencing higher rates of Grade 3 mucosal toxicity (4% vs 1% in younger patients) 7.
The key is aggressive supportive care now and preventive strategies (particularly oral cryotherapy for the fluorouracil component) for future cycles to reduce both severity and impact on quality of life.